Fresenius Kabi has a strong track record of manufacturing reliability, award-winning supply, and support offerings

Fresenius Kabi provides comprehensive patient support

KabiCare Program

Centralized HCP portal for submitting enrollments and tracking patient status

Dedicated support to address access challenges, including benefits investigation/verification, prior authorization, and appeals

Financial support, including copay assistance with out-of-pocket costs as little as $0 for commercially insured patients prescribed STIMUFEND® (pegfilgrastim-fpgk)†

Bridge to Therapy program to avoid treatment delay (eligibility criteria apply†)

To access the HCP portal visit kabicare.trialcard.com and set up an account. To download the enrollment form, visit kabicare.us.

Additional patient support available throughout their treatment journey

Educational resources designed for patients about disease, medication, and health and well-being

Identifying potential treatment-related transportation and lodging benefits with patient’s insurance or providing a list of independent foundations‡

KabiCare clinical support can provide medication counseling and answer questions your patient may have about their Fresenius Kabi biosimilar

Download Patient Brochure
pending

Call 1-888-391-6300 1-888-391-6300 to connect with a Field Reimbursement Manager, who is available to share the latest updates in payer coverage and to help providers secure access and coverage for patients. They can assist with billing and coding, reimbursement, and KabiCare patient support offerings

 

To learn more,
please visit www.KabiCare.us or call
1-833-KABICARE1-833-KABICARE
(1-833-522-42271-833-522-4227)

 
†Eligibility criteria apply. Patients are not eligible for commercial copay assistance or Bridge to Therapy program support if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.
‡Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.
§Nurse support provided by KabiCare is not meant to replace discussions with a healthcare provider regarding a patient’s care and treatment.

KabiCare provides additional support programs to eligible patients.*

Commercial or private insurance

Patients with commercial or private insurance may be eligible* for the commercial copay support program that lowers out-of-pocket costs to as little as $0/month for STIMUFEND® (pegfilgrastim-fpgk) with annual maximum.

To access the HCP portal visit kabicare.trialcard.com and set up an account. To download the enrollment form, visit kabicare.us.

Government insurance (Medicare/Medicaid)

Patients with government insurance that does not cover STIMUFEND may be eligible for assistance through the Patient Assistance Program (PAP) or through independent nonprofit patient assistance programs that me be able to help afford STIMUFEND copay costs.†

Connect with a Patient Support Guide, call 1-833-KABICARE 1-833-KABICARE (1-833-522-42271-833-522-4227).

Uninsured/Underinsured‡

Patients who do not have insurance and/or cannot afford STIMUFEND may be eligible for additional assistance through the Patient Assistance Program (PAP). Talk to your patients about the cost savings of a biosimilar, including STIMUFEND.

Connect with a Patient Support Guide, call 1-833-KABICARE 1-833-KABICARE (1-833-522-42271-833-522-4227).

 

 

To learn more,
please visit www.KabiCare.us or call
1-833-KABICARE1-833-KABICARE
(1-833-522-42271-833-522-4227)

 
*Eligibility criteria apply. Patients are not eligible for commercial copay assistance if the prescription is eligible to be reimbursed, in whole or in part, by any state or federal healthcare program.
†Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Fresenius Kabi has no control over these programs.
‡Underinsured means that your patient’s health insurance plan does not cover STIMUFEND.

Healthcare Common Procedure Coding System (HCPCS) Code1*

HCPCS Q-Code assigned to STIMUFEND for Centers for Medicare & Medicaid Services (CMS) claims processing effective for dates of service
on and after April 1, 2023.

HCPCS Code Description Sites of Service
Q5127 Injection, pegfilgrastim-fpgk,
biosimilar, (STIMUFEND), 0.5 mg
  • Physician office
  • Hospital outpatient
Billable Units Description Details
12 Billable units for administration
of 1 syringe		 If applicable, discarded product should be reported on a separate line with Q5127 and the JW modifier

Payment status indicator2

Identifies whether a service represented by a CPT or HCPCS code is payable under the Outpatient Prospective Payment System (OPPS)
Ambulatory Payment Classification (APC) or another payment system. Only 1 status indicator is assigned to each CPT or HCPCS code.

HCPCS Code Description Status Indicator
Q5127 Injection, pegfilgrastim-fpgk,
biosimilar, (STIMUFEND), 0.5 mg		 K

Download Billing and Coding Information

*The content provided on this page is for informational purposes only and is not intended as legal advice or to replace a medical provider's professional judgment. It is the sole responsibility of the treating healthcare professional to confirm coverage, coding, and claim submission guidance with the patient's health insurance plan. Fresenius Kabi does not guarantee STIMUFEND coverage or reimbursement. The information is current as of March 2023.

We support the needs of all decision-makers

Fresenius Kabi provides collaborative support that streamlines delivery of pegfilgrastim to more patients.

We are committed to addressing the needs of the oncology community with3:

  • Over 25 years of experience supplying oncology medications in the United States
  • One of the largest injectable oncology portfolios in the industry, with 82% of products filled and finished in the United States
  • Over 30 products used in more than 460 different chemotherapy regimens
  • Over 220 chemotherapy regimens that can be supported entirely by Fresenius Kabi

Winner of the FDA Drug Shortage Assistance Award.

pending

Fresenius Kabi strives to make STIMUFEND consistently available

With 90 centers of science, manufacturing, and research and development around the globe, Fresenius Kabi can leverage a first-class supply chain to increase access to essential medicines and medical devices for patients. We plan to invest almost 1 billion dollars over the next few years in new US plants, to double production capacity, and in supply chain expansion, to build in supply chain redundancies. Our advanced manufacturing processes allow us to scale production to meet market needs.

We also partner closely with the FDA and other stakeholders, including other government agencies, pharmaceutical wholesalers, professional associations, and group purchasing organizations.

pending

Learn More About Our Biosimilars

Product replacement program

Fresenius Kabi may provide healthcare professionals with a replacement of STIMUFEND†

Offer applies to product that has been rendered unusable through unintentional, unplanned circumstances, including:

  • Product was mishandled, dropped, broken, or used incorrectly
  • Product was stored incorrectly
  • There was an unforeseen event that caused damage to the product
  • There was an error in mixing or preparing the product

To request a product replacement:

Download Replacement Form
or call customer service at
1-888-386-1300
†Fresenius Kabi reserves the right to reject a request for a product replacement in accordance with its STIMUFEND product replacement policy. Product dispensed through a specialty pharmacy is not eligible for product replacement. Additional eligibility requirements and limitations apply. See product replacement form for more details.
pending

Fresenius Kabi has dedicated more than 100 years to supporting patient care

 
Discover Useful Resources
References:
  1. CMS.gov. Centers for Medicare and Medicaid Services (CMS) Healthcare Common Procedure Coding System (HCPCS) application summaries and coding recommendations. Updated October 1, 2022. Accessed March 16, 2023. https://www.cms.gov/files/document/2022-hcpcs-application-summary-quarter-4-2022-drugs-and-biologicals-updated-02/01/2023.pdf
  2. CMS.gov. April 2023 update of the hospital outpatient prospective payment system (OPPS). Updated March 10, 2023. Accessed March 31, 2023. https://www.cms.gov/files/document/r11897cp.pdf
  3. Data on file. Fresenius Kabi USA, LLC.

FDA, US Food and Drug Administration; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor.